Phase 2 N=117 Navelbine And Radiotherapy in Locally Advanced Lung Cancer
Non-small Cell Lung Cancer
Primary: Local Failure Free Survival — 9.4; 9.9 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=15 Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Progression Free Survival — 9.4 months
Phase 2 N=19 Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
Lung Cancer
Primary: Toxic Death Rate — NA Participants
Phase 2 N=46 Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Phase 2 N=84 Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer
Primary: Overall Survival and Progression Free Survival — 29; 12.9; 22 percentage of participants
Phase 2 N=71 Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: The Primary Goal of This Study is to Show That the Addition of Bevacizumab to Cisplatin-based Chemotherapy in the Neoadjuvant Setting for Non-squamous Cell Carcinomas…
Phase 2 N=10 Locally Advanced NSCLC Hyperfractionated RT
Carcinoma, Non Small Cell Lung (NSCLC)
Primary: The Metabolic Complete Response Rate, Assessed Using Interim PET-CT, in an Accelerated Fashion (2 Gy/Fraction, 6 Fractions/Week) With Concurrent Chemotherapy — 1; 6; 1…
Phase 2 N=11 LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
Phase 3 N=598 Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Overall Survival — 26.81; 24.97 months — p=0.831
Phase 2 N=25 The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial
Non-small Cell Lung Cancer, NSCLC
Primary: Progression-Free Survival (PFS) — 19 Participants
Phase 2 N=53 The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
N/A N=35 Stereotactic Body Radiation Therapy in Stage II/III Non Small Cell Lung Cancer
Lung Cancer
Primary: Boost Dose Toxicity — 5 Participants
Phase 2 N=98 Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC
STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER
Primary: 2-year Overall Survival (Phase II) — 66.5; 55.5 percentage of participants
Phase 2 N=32 Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
Lung Neoplasms · Carcinoma, Non-small Cell Lung
Primary: Percentage of Participants With Objective Response (OR) — 9.4 Percentage of participants
Phase 2 N=75 Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer
Lung Cancer
Primary: Pathologic Complete Response Rate — 0 Percentage of participants
Phase 2 N=82 Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 29; 50 percentage of participants
Phase 2 N=27 Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)
Lung Cancer
Primary: Median Progression Free Survival (PFS) — 7.5 months
Phase 2 N=181 A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Major Pathologic Response (MPR) — 20.3 percentage of participants — p=<.0001
Phase 2 N=75 Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Lung Cancer
Primary: Overall Survival at 12 Months — 57 percentage of participants
Phase 3 N=260 Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Survival Without Grade 3 or 4 Toxicity — 3.2; 0.7 months — p=<0.001
Phase 4 N=49 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation
Carcinoma, Large Cell · Neuroendocrine Tumors
Primary: Percentage of Participants Progression-free — 49.0 Percentage of participants
Phase 2 N=24 Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer
Primary: Percentage of Subjects With Detectable Circulating T Cells After Treatment — 16.7 Percentage of participants
N/A N=29 Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Phase 2 N=105 Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Primary: Progression Free Survival (PFS) at 18-month — 65.5; 66.3 Percentage of participants
Phase 2 N=84 A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Proportion of Subjects Surviving at One Year — 0.405 proportion
Phase 2 N=79 NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
Non-small Cell Lung Cancer Stage III
Primary: Grade ≥3 Pneumonitis (CTCAE v4.0) up to 6 Months Post-radiotherapy — 71 Participants
Phase 2 N=137 A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 19.1; 19.0; 8.3 weeks — p=0.2133
Phase 3 N=243 Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Overall Survival — 21.5; 24.1 Months — p=0.883
Phase 2 N=90 A Study of Pemetrexed and Cisplatin, in Non Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: 1 Year Progression Free Survival — 53.7 percentage of participants — p=0.0645
Phase 2 N=101 Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer
Lung Cancer
Primary: 18 Month Survival — 58; 54 percentage of participants